Liangning Hu

605 total citations
27 papers, 400 citations indexed

About

Liangning Hu is a scholar working on Molecular Biology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Liangning Hu has authored 27 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 17 papers in Hematology and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Liangning Hu's work include Multiple Myeloma Research and Treatments (10 papers), Histone Deacetylase Inhibitors Research (9 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Liangning Hu is often cited by papers focused on Multiple Myeloma Research and Treatments (10 papers), Histone Deacetylase Inhibitors Research (9 papers) and PI3K/AKT/mTOR signaling in cancer (5 papers). Liangning Hu collaborates with scholars based in China and United States. Liangning Hu's co-authors include Jumei Shi, Gege Chen, Bingqian Xie, Xiaosong Wu, Guang Yang, Weiliang Zhu, Zhijian Xu, Tao Yi, Lu Gao and Yuanyuan Kong and has published in prestigious journals such as Blood, Scientific Reports and International Journal of Molecular Sciences.

In The Last Decade

Liangning Hu

26 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Liangning Hu China 11 265 81 80 69 67 27 400
Bingqian Xie China 11 239 0.9× 73 0.9× 78 1.0× 71 1.0× 59 0.9× 16 381
Savita Bhalla United States 9 211 0.8× 109 1.3× 30 0.4× 37 0.5× 53 0.8× 19 355
Sheila Prachand United States 9 328 1.2× 184 2.3× 52 0.7× 43 0.6× 72 1.1× 20 572
Changshan Yang China 13 362 1.4× 164 2.0× 42 0.5× 54 0.8× 28 0.4× 14 546
Kevin Shoulars United States 13 159 0.6× 49 0.6× 92 1.1× 42 0.6× 33 0.5× 23 377
Harriet S. Walter United Kingdom 10 213 0.8× 145 1.8× 45 0.6× 53 0.8× 103 1.5× 39 456
Joo‐Yun Byun South Korea 8 228 0.9× 56 0.7× 17 0.2× 31 0.4× 32 0.5× 29 365
Shuoyi Jiang China 9 289 1.1× 80 1.0× 36 0.5× 73 1.1× 30 0.4× 12 439
Manel Jendoubi France 9 256 1.0× 81 1.0× 27 0.3× 117 1.7× 84 1.3× 14 453

Countries citing papers authored by Liangning Hu

Since Specialization
Citations

This map shows the geographic impact of Liangning Hu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Liangning Hu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Liangning Hu more than expected).

Fields of papers citing papers by Liangning Hu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Liangning Hu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Liangning Hu. The network helps show where Liangning Hu may publish in the future.

Co-authorship network of co-authors of Liangning Hu

This figure shows the co-authorship network connecting the top 25 collaborators of Liangning Hu. A scholar is included among the top collaborators of Liangning Hu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Liangning Hu. Liangning Hu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Shufen, Ruo‐Yu Dong, Ping Yu, et al.. (2025). KDM6A Deficiency Induces Myeloid Bias and Promotes CMML‐Like Disease Through JAK/STAT3 Activation by Repressing SOCS3. Advanced Science. 12(21). e2413091–e2413091.
2.
Hu, Liangning, Xiaoyan Yue, Zijun Qian, et al.. (2024). Association between the pre-transplantation serum ferritin level and outcomes of hematopoietic stem cell transplantation: A systematic review and meta-analysis. Heliyon. 10(18). e37436–e37436. 2 indexed citations
3.
Gao, Xuejie, Liangning Hu, Ke Hu, et al.. (2024). EZH2 inhibition induces senescence via ERK1/2 signaling pathway in multiple myeloma. Acta Biochimica et Biophysica Sinica. 56(7). 1055–1064. 1 indexed citations
4.
Wang, Shufen, Xiaoyan Yue, Hongyu Zhou, et al.. (2023). The association of intestinal microbiota diversity and outcomes of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis. Annals of Hematology. 102(12). 3555–3566. 3 indexed citations
5.
He, Wan, Bo Li, Jinfeng Zhou, et al.. (2020). Novel cyclophosphamide of natural products osalmide and pterostilbene induces cytotoxicity and cell cycle arrest in diffuse large B-cell lymphoma cells. Acta Biochimica et Biophysica Sinica. 52(4). 401–410. 6 indexed citations
6.
He, Wan, Zhijian Xu, Dongliang Song, et al.. (2020). Antitumor effects of rafoxanide in diffuse large B cell lymphoma via the PTEN/PI3K/Akt and JNK/c-Jun pathways. Life Sciences. 243. 117249–117249. 19 indexed citations
7.
Chen, Gege, Ke Hu, Haiguo Sun, et al.. (2020). A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib. Cancer Letters. 478. 45–55. 7 indexed citations
8.
Hu, Liangning, Bo Li, Gege Chen, et al.. (2020). A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe. Journal of Experimental & Clinical Cancer Research. 39(1). 105–105. 7 indexed citations
9.
Lu, Kang, Bo Li, Zhijian Xu, et al.. (2020). A novel silicone derivative of natural osalmid (DCZ0858) induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma via the JAK2/STAT3 pathway. Signal Transduction and Targeted Therapy. 5(1). 31–31. 17 indexed citations
10.
Zhang, Ting, Bo Li, Zhijian Xu, et al.. (2019). DCZ0801, a novel compound, induces cell apoptosis and cell cycle arrest via MAPK pathway in multiple myeloma. Acta Biochimica et Biophysica Sinica. 51(5). 517–523. 9 indexed citations
11.
Kong, Yuanyuan, Bo Li, Lu Gao, et al.. (2019). <p>DCZ0814 induces apoptosis and G0/G1 phase cell cycle arrest in myeloma by dual inhibition of mTORC1/2</p>. Cancer Management and Research. Volume 11. 4797–4808. 2 indexed citations
12.
Kong, Yuanyuan, Liangning Hu, Lu Kang, et al.. (2019). Ferroportin downregulation promotes cell proliferation by modulating the Nrf2–miR-17-5p axis in multiple myeloma. Cell Death and Disease. 10(9). 624–624. 65 indexed citations
13.
14.
Hou, Jun, Huiqun Wu, Yongsheng Xie, et al.. (2018). Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy. Neoplasma. 65(5). 720–729. 8 indexed citations
15.
Yu, Dandan, Yong Zhang, Gege Chen, et al.. (2018). Targeting the PI3K/Akt/mTOR signaling pathway by pterostilbene attenuates mantle cell lymphoma progression. Acta Biochimica et Biophysica Sinica. 50(8). 782–792. 15 indexed citations
16.
Chen, Gege, Zhijian Xu, Jun Hou, et al.. (2017). The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells. Oncology Reports. 38(1). 488–496. 13 indexed citations
17.
18.
Xin, Hongchuan, et al.. (2017). A green catalytic method for selective synthesis of iodophenols via aerobic oxyiodination under organic solvent-free conditions. Catalysis Communications. 93. 1–4. 8 indexed citations
19.
Kong, Yuanyuan, Gege Chen, Zhijian Xu, et al.. (2016). Pterostilbene induces apoptosis and cell cycle arrest in diffuse large B-cell lymphoma cells. Scientific Reports. 6(1). 37417–37417. 60 indexed citations
20.
Xie, Bingqian, Zhijian Xu, Guang Yang, et al.. (2016). Antitumor effect of dobutamine on multiple myeloma via mitogen-activated protein kinase  pathwayin vitro. Acta Biochimica et Biophysica Sinica. 48(12). 1135–1137. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bingqian Xie Breakdown of academic impact, for papers by Savita Bhalla Breakdown of academic impact, for papers by Sheila Prachand Breakdown of academic impact, for papers by Changshan Yang Breakdown of academic impact, for papers by Kevin Shoulars Breakdown of academic impact, for papers by Harriet S. Walter Breakdown of academic impact, for papers by Joo‐Yun Byun Breakdown of academic impact, for papers by Shuoyi Jiang Breakdown of academic impact, for papers by Manel Jendoubi
Rankless by CCL
2026